Okami Medical announced today that it closed a $32.5 million financing round to support its catheter-based technologies.
Aliso Viejo, California-based Okami develops multiple technologies for peripheral vascular occlusion. To date, it developed the LOBO (low-profile braided occluder) vascular occlusion system and the Sendero microcatheter.
LOBO provides interventional physicians with a single-device, one-and-done solution for occluding a wide range of arterial targets. It also eliminates the need for multiple embolic devices. Its proprietary HDBraid technology creates a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure. The platform enables the fast and efficient closure of blood vessels throughout the body to help treat a diverse set of conditions.
Sendero enables the smooth delivery of interventional devices while providing optimal trackability through tortuous peripheral vessels. Okami designed the FDA-cleared system for the delivery of LOBO-3 and LOBO-5 devices. The system incorporates a hydrophilic coating, stainless steel braid and radiopaque market band. This optimizes trackability and enables the precise placement of interventional devices. Meanwhile, a lubricious PTFE inner liner allows for the low-friction delivery of interventional devices.
New investor Vensana Capital led the financing. Existing investors, including U.S. Venture Partners, members of the Okani board and other industry veterans, also joined in.
“We are honored to have the support of Vensana and our existing investors to advance these important technologies and deliver them to patients,” said Rhonda Robb, president and CEO of Okami. “We are also grateful for the support and contributions of our employees and physician partners as we work tirelessly to build the market leader in vascular occlusion.”
